UP!
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: PTCT |
| Industry | Pharmaceuticals |
| Headquarters | South Plainfield, New Jersey, United States |
| Website | ptcbio |
Coordinates: 40°33′03″N 74°25′23″W / 40.550722°N 74.423071°W / 40.550722; -74.423071
PTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs that regulate gene expression by targeting post-translational control (PTC) mechanisms in orphan diseases.
Since 2003, PTC has been working on a drug for Duchenne muscular dystrophy.
In September 2009, PTC has entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases.
As of May 2016, PTC portfolio includes small-molecule compounds for treatment of spinal muscular atrophy (RG7916) and Duchenne muscular dystrophy (Ataluren and another exon skipping compound).
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-10-26 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | -2.13 | -2.13 |
| Q1 2022 | 2022-05-03 | -1.78 | -1.78 |
| Q4 2021 | 2022-02-22 | -2.03 | -2.03 |
| Q3 2021 | 2021-10-28 | -1.89 | -1.89 |
| Q2 2021 | 2021-07-29 | -1.68 | -1.68 |
| Q1 2021 | 2021-05-04 | -1.83 | -1.83 |
| Q4 2020 | 2021-02-25 | -1.08 | -1.08 |
| Q3 2020 | 2020-10-29 | 0.00 | 0.00 |
| Q2 2020 | 2020-08-05 | -2.78 | -2.78 |
| 2016-05-06 | Reiterated Rating | Jefferies Group | Hold | $8.00 |
| 2016-05-06 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-05-06 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-04-18 | Reiterated Rating | RBC Capital | Sector Perform | $9.00 |
| 2016-04-18 | Reiterated Rating | Royal Bank Of Canada | Sector Perform | $9.00 |
| 2016-04-17 | Reiterated Rating | Oppenheimer | Buy | $39.00 |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Hold | |
| 2016-04-17 | Reiterated Rating | Oppenheimer Holdings Inc. | Buy | $39.00 |
| 2016-03-23 | Reiterated Rating | Wedbush | Neutral | $11.00 |
| 2016-03-01 | Lower Price Target | Jefferies Group | Hold | $12.00 to $8.00 |
| 2016-03-01 | Downgrade | Cowen and Company | Outperform to Market Perform | |
| 2016-03-01 | Downgrade | Wedbush | Outperform to Neutral | $27.00 to $11.00 |
| 2016-03-01 | Reiterated Rating | Credit Suisse | Outperform | $36.00 to $12.00 |
| 2016-03-01 | Boost Price Target | Barclays | Overweight | $40.00 to $100.00 |
| 2016-03-01 | Boost Price Target | RBC Capital | Sector Perform | $9.00 to $11.00 |
| 2016-03-01 | Boost Price Target | Barclays PLC | Overweight | $40.00 to $100.00 |
| 2016-02-29 | Reiterated Rating | Oppenheimer | Buy | $111.00 to $39.00 |
| 2016-02-29 | Downgrade | Bank of America | Buy to Neutral | |
| 2016-02-29 | Downgrade | Bank of America Corp. | Buy to Neutral | |
| 2016-02-24 | Lower Price Target | Wedbush | Outperform | $65.00 to $27.00 |
| 2016-02-24 | Downgrade | Citigroup Inc. | Buy to Neutral | $90.00 to $13.00 |
| 2016-02-24 | Upgrade | Jefferies Group | Underperform to Hold | $18.00 to $12.00 |
| 2016-02-24 | Downgrade | RBC Capital | Outperform to Sector Perform | $56.00 to $11.00 |
| 2016-02-24 | Reiterated Rating | Cowen and Company | Outperform | $120.00 |
| 2016-02-23 | Reiterated Rating | Oppenheimer | Buy | $135.00 to $111.00 |
| 2016-02-23 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $81.00 to $22.00 |
| 2016-02-08 | Reiterated Rating | Cowen and Company | Outperform | $120.00 |
| 2016-02-01 | Reiterated Rating | Oppenheimer | Outperform | $135.00 |
| 2016-01-19 | Initiated Coverage | Credit Suisse | Outperform | $36.00 |
| 2016-01-07 | Reiterated Rating | Wedbush | Outperform | $65.00 |
| 2016-01-05 | Reiterated Rating | Oppenheimer | Outperform | $135.00 |
| 2015-12-21 | Reiterated Rating | Oppenheimer | Buy | $135.00 |
| 2015-11-25 | Downgrade | Jefferies Group | Hold to Underperform | $26.00 to $18.00 |
| 2015-11-23 | Reiterated Rating | Oppenheimer | Outperform | $135.00 |
| 2015-11-12 | Reiterated Rating | Cowen and Company | Outperform | $120.00 |
| 2015-11-11 | Reiterated Rating | Oppenheimer | Outperform | $135.00 |
| 2015-10-22 | Initiated Coverage | Jefferies Group | Hold | $26.00 |
| 2015-10-18 | Reiterated Rating | Barclays | Buy | $100.00 |
| 2015-10-17 | Reiterated Rating | Oppenheimer | Buy | |
| 2015-10-16 | Lower Price Target | Wedbush | Outperform | $81.00 to $65.00 |
| 2015-10-16 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $100.00 to $84.00 |
| 2015-10-16 | Lower Price Target | Oppenheimer | Outperform | $155.00 to $135.00 |
| 2015-10-16 | Lower Price Target | RBC Capital | Outperform | $85.00 to $56.00 |
| 2015-10-16 | Reiterated Rating | Roth Capital | Hold | $63.00 |
| 2015-10-01 | Reiterated Rating | Oppenheimer | Outperform | $155.00 |
| 2015-09-20 | Reiterated Rating | Oppenheimer | Outperform | $155.00 |
| 2015-09-18 | Downgrade | Roth Capital | Hold | |
| 2015-08-25 | Initiated Coverage | Citigroup Inc. | Buy | $90.00 |
| 2015-08-23 | Reiterated Rating | Roth Capital | Neutral | |
| 2015-08-03 | Reiterated Rating | Roth Capital | Hold | |
| 2015-07-31 | Boost Price Target | RBC Capital | Outperform | $81.00 to $85.00 |
| 2015-07-15 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | $74.00 to $100.00 |
| 2015-07-10 | Reiterated Rating | Roth Capital | Neutral | $63.00 |
| 2015-06-24 | Set Price Target | Oppenheimer | Buy | $155.00 |
| 2015-06-17 | Reiterated Rating | Deutsche Bank | Buy | $115.00 |
| 2015-06-17 | Reiterated Rating | Deutsche Bank AG | Buy | $115.00 |
| 2015-06-11 | Reiterated Rating | RBC Capital | Outperform | $91.00 |
| 2015-05-06 | Reiterated Rating | Deutsche Bank | Buy | $115.00 |
| 2015-05-05 | Reiterated Rating | Credit Suisse | Outperform | $100.00 |
| 2015-05-05 | Set Price Target | Oppenheimer | Buy | $155.00 |
| 2015-05-05 | Downgrade | Roth Capital | Buy to Neutral | $75.00 to $63.00 |
| 2015-04-24 | Reiterated Rating | RBC Capital | Outperform | $81.00 |
| 2015-04-23 | Boost Price Target | Oppenheimer | Outperform | $135.00 to $155.00 |
| 2015-04-16 | Upgrade | Cowen and Company | Market Perform to Outperform | |
| 2015-04-09 | Boost Price Target | Deutsche Bank | Buy | $75.00 to $115.00 |
| 2015-03-03 | Initiated Coverage | Barclays | Overweight | $100.00 |
| 2015-03-02 | Boost Price Target | Wedbush | $81.00 | |
| 2015-03-02 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | |
| 2015-03-02 | Boost Price Target | Roth Capital | Buy | $58.00 to $75.00 |
| 2015-02-24 | Reiterated Rating | Deutsche Bank | Buy | |
| 2015-02-24 | Boost Price Target | Credit Suisse | $100.00 | |
| 2015-01-22 | Set Price Target | Deutsche Bank | Buy | $75.00 |
| 2015-01-22 | Initiated Coverage | RBC Capital | Outperform | $81.00 |
| 2014-12-23 | Initiated Coverage | Wedbush | Outperform | |
| 2014-12-18 | Initiated Coverage | Citigroup Inc. | Buy | $81.00 |
| 2014-12-04 | Upgrade | Credit Suisse | Top Pick | |
| 2014-11-07 | Set Price Target | Credit Suisse | Outperform | $55.00 to $66.00 |
| 2014-10-13 | Reiterated Rating | Bank of America | Buy | $50.00 to $48.00 |
| 2014-10-06 | Downgrade | Cowen and Company | Outperform to Market Perform | |
| 2014-09-29 | Reiterated | ROTH Capital | Buy | $43 to $58 |
| 2014-09-29 | Boost Price Target | Roth Capital | Buy | $43.00 to $58.00 |
| 2014-09-24 | Boost Price Target | Credit Suisse | Outperform | $40.00 to $55.00 |
| 2014-09-23 | Reiterated Rating | Bank of America | Buy | $37.00 to $50.00 |
| 2014-09-15 | Initiated Coverage | Deutsche Bank | Buy | $75.00 |
| 2014-08-18 | Boost Price Target | Roth Capital | Buy | $34.00 to $43.00 |
| 2014-07-31 | Initiated Coverage | Oppenheimer | Outperform | $60.00 |
| 2014-07-22 | Initiated Coverage | Bank of America | Buy | $37.00 |
| 2014-07-10 | Initiated Coverage | Barclays | Overweight | |
| 2014-07-07 | Initiated Coverage | Roth Capital | Buy | $34.00 |
| 2014-05-23 | Boost Price Target | Credit Suisse | $35.00 to $40.00 | |
| 2014-02-27 | Initiated Coverage | B. Riley | Buy | |
| 2014-02-18 | Boost Price Target | Credit Suisse | $24.00 to $35.00 | |
| 2014-01-30 | Upgrade | JPMorgan Chase & Co. | Overweight | |
| 2013-11-08 | Boost Price Target | Wedbush | Outperform | $31.00 to $35.00 |
| 2013-11-08 | Boost Price Target | Evercore ISI | Overweight | $30.00 to $34.50 |
| 2013-09-23 | Reiterated Rating | Wedbush | Buy |
| 2016-05-06 | Reiterated Rating | Jefferies Group | Hold | $8.00 |
| 2016-05-06 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-05-06 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-04-18 | Reiterated Rating | RBC Capital | Sector Perform | $9.00 |
| 2016-04-18 | Reiterated Rating | Royal Bank Of Canada | Sector Perform | $9.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In PTCT 169 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| FMR LLC | 10.73M |
| WELLINGTON MANAGEMENT CO LLP | 7.49M |
| Vanguard Group, Inc | 7.21M |
| BlackRock Inc. | 6.11M |
| RTW INVESTMENTS, LLC | 5.62M |
| FRANKLIN RESOURCES INC | 4.47M |
| ARMISTICE CAPITAL, LLC | 2.90M |
| STATE STREET CORP | 2.82M |
| Camber Capital Management LLC | 2.45M |
| HENDERSON GROUP PLC | 2.08M |
| LOOMIS SAYLES & CO L P | 1.62M |
| BlackRock Fund Advisors | 1.57M |
| MACQUARIE GROUP LTD | 1.56M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.47M |
| GEODE CAPITAL MANAGEMENT, LLC | 1.28M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| HBM Healthcare Investments (Cayman) Ltd. | 8.12% (2441504) | OPHT / PTCT / TSPT / |
| Koppel Adam | 7.76% (2333333) | BIIB / DRNA / PTCT / TRVN / |
| CREDIT SUISSE AG/ Former 10% Owner | 7.51% (2256882) | AFFY / PTCT / STRI / WD / |
| Vulcan Ventures Inc. | 2.67% (803067) | ADNC / PTCT / |
| Hirawat Claudia de Oliveira Ribeiro President | 0.13% (39247) | PTCT / |
| Kovacs Shane William Charles Chief Financial Officer | 0.13% (37850) | PTCT / |
| Rothera Mark Chief Commercial Officer | 0.11% (33739) | AEGR / PTCT / |
| Boulding Mark Elliott Exec. VP, and CLO | 0.09% (27034) | PTCT / |
| Peltz Stuart Walter Chief Executive Officer | 0.09% (26646) | PTCT / |
| Graham Dawn | 0.08% (25000) | ECYT / MDVN / PTCT / XENE / |
| SOUTHWELL DAVID P | 0.08% (23604) | PTCT / RCKT / TCRD / |
| Bolte Axel | 0.07% (20000) | OPHT / PTCT / |
| Jacobson Allan Steven | 0.02% (6848) | PTCT / |
| Utter Christine Marie Principal Financial Officer | 0.02% (6660) | PTCT / |
| Ong Tuyen Chief Medical Officer | 0.02% (6000) | PTCT / |
| Almstead Neil Gregory Senior VP, Research and CMC | 0.02% (5125) | PTCT / |
| Spiegel Robert J. Chief Medical Officer | 0.01% (3239) | CAPS / GERN / PTCT / SCMP / |
| Kranda Michael L | 0.01% (2242) | PTCT / |
| Souza Marcio Chief Operating Officer | 0.01% (1742) | PTCT / |
UM